Abstract: Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation. The disclosure also provides pharmaceutically acceptable compositions comprising compounds and methods for the treatment of EGFR mutant-related cancers.

Abstract: Disclosed herein are bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation of mutant EGFR kinase, and methods of preparation and uses thereof.

Abstract: Disclosed herein are novel pharmaceutically active compounds and their preparation methods. The compounds inhibit mutant EGFR and are useful in the treatment of oncological diseases.

Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

Abstract: The present disclosure discloses a method for identifying a boundary of a sedimentary facies, a computer device and a computer readable storage medium. The method comprises: acquiring a preliminary marked result of the sedimentary facies in a seismic attribute map; acquiring a color-based K-means classification result of the seismic attribute map by using a maximal between-cluster variance and a K-means clustering; acquiring a super-pixel classification result of the seismic attribute map according to a SLIC super-pixel segmentation; and performing a region growing fusion on the super-pixel classification result by taking the preliminary marked result and the K-means classification result as constraints, to determine an identification result of the boundary of the sedimentary facies in the seismic attribute map.

Abstract: A color filter substrate, a manufacturing method thereof, and a corresponding display panel. The manufacturing method of the color filter substrate includes: providing a substrate; forming an array of a plurality of pixel units on the substrate, wherein each pixel unit comprises a first sub-pixel, a second sub-pixel and at least two third sub-pixels, the at least two third sub-pixels being made of an irreversible temperature-sensitive pigment; and performing a temperature-variation treatment on one third sub-pixel in each pixel unit such that the one third sub-pixel changes color and becomes a fourth sub-pixel.

Abstract: The present disclosure discloses a method for identifying a boundary of a sedimentary facies, a computer device and a computer readable storage medium. The method comprises: acquiring a preliminary marked result of the sedimentary facies in a seismic attribute map; acquiring a color-based K-means classification result of the seismic attribute map by using a maximal between-cluster variance and a K-means clustering; acquiring a super-pixel classification result of the seismic attribute map according to a SLIC super-pixel segmentation; and performing a region growing fusion on the super-pixel classification result by taking the preliminary marked result and the K-means classification result as constraints, to determine an identification result of the boundary of the sedimentary facies in the seismic attribute map.

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

Abstract: A method for detecting clogging of a subsurface flow constructed wetland, including the steps of firstly emptying water in the subsurface flow constructed wetland, and then measuring the apparent resistivity of the subsurface flow constructed wetland bed after the water is emptied, wherein the water holding capacity of clogging sediments in the clogged region after emptying is strong, the apparent resistivity of this region is further measured to be lower than an unclogged region and the clogged region can thus be positioned and analyzed, the apparent resistivity of the region clogged more seriously is lower and the degree of clogging can thus be quantitatively analyzed.

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

Abstract: A method for detecting clogging of a subsurface flow constructed wetland, including the steps of firstly emptying water in the subsurface flow constructed wetland, and then measuring the apparent resistivity of the subsurface flow constructed wetland bed after the water is emptied, wherein the water holding capacity of clogging sediments in the clogged region after emptying is strong, the apparent resistivity of this region is further measured to be lower than an unclogged region and the clogged region can thus be positioned and analyzed, the apparent resistivity of the region clogged more seriously is lower and the degree of clogging can thus be quantitatively analyzed.

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

Abstract: A color filter substrate, a manufacturing method thereof, and a corresponding display panel. The manufacturing method of the color filter substrate includes: providing a substrate; forming an array of a plurality of pixel units on the substrate, wherein each pixel unit comprises a first sub-pixel, a second sub-pixel and at least two third sub-pixels, the at least two third sub-pixels being made of an irreversible temperature-sensitive pigment; and performing a temperature-variation treatment on one third sub-pixel in each pixel unit such that the one third sub-pixel changes color and becomes a fourth sub-pixel.

Abstract: A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract: The present invention provides a method, terminal and system for fiber network management. A terminal obtains configuration information from a management system and sending an identifier of a configuration port connected to a fiber to an Optical Distribution Network (ODN) device to allow the ODN device to indicate, according to the configuration port identifier, a corresponding configuration port into which one end of the fiber is inserted. The method includes sending, according to a received first identifier of one end of the fiber and a corresponding configuration port identifier, which are sent by the ODN device, and a second identifier of an other end of the fiber, an identifier of a peer configuration port connected to the fiber to the ODN device to allow the ODN device to indicate, a corresponding peer configuration port into which the other end of the fiber is inserted.

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

Abstract: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

Abstract: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).